TVM Capital Life Science
Stefan Fischer has been with TVM Capital Life Science since September 2000, holding various titles including Managing Partner (Finance), CFO, General Partner / CFO, and General Partner Corporate Finance. Prior to this, Stefan worked at KPMG Corporate Finance as a Senior Executive from September 1997 to August 2000. Stefan obtained their Dipl.-Kfm., BWL degree from Universität Passau in 1997.
TVM Capital Life Science
TVM is a leading international venture capital firm focused on investing in life science innovations. The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care. TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics. The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.